This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

C. DWIGHT TOWNES, M.D.

Arch Ophthalmol. 1960;64(1):108-113.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Since the introduction by Barraquer of enzymatic zonulolysis using -chymotrypsin to produce lysis of the zonular fibers and facilitate intracapsular removal of cataract, many reports from all parts of the world have appeared in the literature describing various authors' experiences with the new method. Invariably they extol the enzyme for its fibrinolytic and proteolytic properties which make removal of the lens easier. At least one prominent ophthalmic surgeon is so enthusiastic he uses -chymotrypsin in all his cataract operations.

Many of the reports mention, without going into details, unfavorable effects such as interference with wound healing and abnormally high incidence of corneal edema, but apparently such unfavorable incidents have not occurred with sufficient frequency or severity to dampen the zeal of the authors for zonulolysis. Very few, among whom are Konstas and Chachamidis,¹ give actual figures for complications (delayed reformation of anterior chamber: 38% with -chymotrypsin, 13% without -chymotrypsin). . . . [Full Text PDF of this Article]

Author Affiliations
Louisville

Professor and Chairman of the Section of Ophthalmology, University of Louisville School of Medicine.

Footnotes
Submitted for publication March 14, 1960.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?